Colgate-Palmolive (CL) Set to Post Earnings on Friday

Key Points

• Colgate-Palmolive is expected to report Q3 2026 results before market open on October 30. Analysts forecast earnings of $0.926 per share and revenue of $5.34 billion, following the company’s prior-quarter EPS beat and 4.9% year-over-year revenue growth.
• Shares opened at $97.44, near their 12-month high of $99.33, while analysts maintain a “Moderate Buy” consensus with an average price target of $98.
• The company declared a quarterly dividend of $0.53 per share, equivalent to a 2.2% yield, while insiders have sold approximately $16.1 million of stock over the past 90 days.

Colgate-Palmolive (NYSE:CL - Get Free Report) will likely be releasing its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to post earnings of $0.9260 per share and revenue of $5.34 billion for the quarter. Investors can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, October 30, 2026 at 8:30 AM ET.

Colgate-Palmolive (NYSE:CL - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.04. Colgate-Palmolive had a return on equity of 464.63% and a net margin of 9.68%. The firm had revenue of $5.36 billion for the quarter, compared to the consensus estimate of $5.36 billion. During the same quarter in the previous year, the business earned $0.92 EPS. The company's quarterly revenue was up 4.9% compared to the same quarter last year. On average, analysts expect Colgate-Palmolive to post $3.87 EPS for the current fiscal year and $4.07 EPS for the next fiscal year.

Colgate-Palmolive Stock Performance

Shares of Colgate-Palmolive stock opened at $97.44 on Friday. The business has a 50-day moving average of $89.22 and a 200 day moving average of $89.31. Colgate-Palmolive has a 12 month low of $74.54 and a 12 month high of $99.33. The stock has a market capitalization of $77.68 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 4.52 and a beta of 0.33. The company has a debt-to-equity ratio of 13.82, a current ratio of 1.03 and a quick ratio of 0.67.

Colgate-Palmolive Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Tuesday, October 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.2%. Colgate-Palmolive's dividend payout ratio is 84.13%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CL. Morgan Stanley reissued an "overweight" rating and set a $104.00 price target (up from $100.00) on shares of Colgate-Palmolive in a research report on Monday, August 3rd. BNP Paribas Exane dropped their price objective on shares of Colgate-Palmolive from $101.00 to $97.00 and set an "outperform" rating for the company in a report on Monday, September 28th. Piper Sandler cut their target price on shares of Colgate-Palmolive from $98.00 to $95.00 and set an "overweight" rating on the stock in a research note on Monday, September 21st. Barclays increased their target price on shares of Colgate-Palmolive from $80.00 to $87.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 21st. Finally, Bank of America decreased their price target on shares of Colgate-Palmolive from $102.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, October 9th. Thirteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $98.00.

Insider Activity at Colgate-Palmolive

In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 10,000 shares of the business's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $92.05, for a total transaction of $920,500.00. Following the completion of the transaction, the chief operating officer owned 64,901 shares in the company, valued at $5,974,137.05. The trade was a 13.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Noel R. Wallace sold 161,021 shares of the firm's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $91.92, for a total transaction of $14,801,050.32. Following the completion of the sale, the chief executive officer owned 362,231 shares in the company, valued at $33,296,273.52. The trade was a 30.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 175,191 shares of company stock valued at $16,110,903 over the last 90 days. 0.43% of the stock is owned by corporate insiders.

About Colgate-Palmolive

Colgate-Palmolive Company NYSE: CL is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill's Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill's Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.